DK1397153T3 - Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler - Google Patents
Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekylerInfo
- Publication number
- DK1397153T3 DK1397153T3 DK02734556T DK02734556T DK1397153T3 DK 1397153 T3 DK1397153 T3 DK 1397153T3 DK 02734556 T DK02734556 T DK 02734556T DK 02734556 T DK02734556 T DK 02734556T DK 1397153 T3 DK1397153 T3 DK 1397153T3
- Authority
- DK
- Denmark
- Prior art keywords
- soluble ctla4
- ctla4 mutant
- islet cell
- mutant molecules
- cell graft
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29340201P | 2001-05-23 | 2001-05-23 | |
PCT/US2002/016708 WO2002094202A2 (en) | 2001-05-23 | 2002-05-23 | Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1397153T3 true DK1397153T3 (da) | 2008-05-26 |
Family
ID=23128937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02734556T DK1397153T3 (da) | 2001-05-23 | 2002-05-23 | Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler |
Country Status (17)
Country | Link |
---|---|
US (2) | US7304033B2 (da) |
EP (1) | EP1397153B1 (da) |
JP (1) | JP4837880B2 (da) |
AT (1) | ATE390931T1 (da) |
AU (1) | AU2002305716B2 (da) |
CA (1) | CA2447921C (da) |
CY (1) | CY1108127T1 (da) |
CZ (1) | CZ305380B6 (da) |
DE (1) | DE60225914T2 (da) |
DK (1) | DK1397153T3 (da) |
ES (1) | ES2302811T3 (da) |
HU (1) | HU229680B1 (da) |
MX (1) | MXPA03010568A (da) |
NO (1) | NO332465B1 (da) |
PL (1) | PL204899B1 (da) |
PT (1) | PT1397153E (da) |
WO (1) | WO2002094202A2 (da) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887471B1 (en) * | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
ATE219376T1 (de) * | 1996-03-20 | 2002-07-15 | Bristol Myers Squibb Co | Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
CA2411962A1 (en) * | 2000-06-09 | 2001-12-20 | Bristol-Myers Squibb Company | Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
CA2413190C (en) * | 2000-07-03 | 2009-04-07 | Bristol-Myers Squibb Company | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
WO2002058729A2 (en) * | 2001-01-26 | 2002-08-01 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
EP1397153B1 (en) * | 2001-05-23 | 2008-04-02 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
PT1576182E (pt) * | 2002-12-23 | 2011-01-21 | Bristol Myers Squibb Co | Optimizador da qualidade do produto em processos de cultura celular de mamíferos destinados à produção de proteínas |
PL377731A1 (pl) * | 2002-12-23 | 2006-02-06 | Bristol-Myers Squibb Company | Sposoby hodowli komórek ssaczych do wytwarzania białka |
KR20060132541A (ko) * | 2003-08-04 | 2006-12-21 | 브리스톨-마이어스 스큅 컴퍼니 | 가용성 ctla4 분자를 사용한 심혈관 질환의 치료 방법 |
US20070009517A1 (en) * | 2003-08-25 | 2007-01-11 | Mark De Boer | Method of inducing immune tolerance |
CA2603970A1 (en) | 2005-04-06 | 2006-10-12 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
US9457070B2 (en) | 2005-06-07 | 2016-10-04 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease |
WO2006133403A2 (en) | 2005-06-07 | 2006-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
US8715649B2 (en) * | 2005-06-07 | 2014-05-06 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity |
WO2007035213A2 (en) * | 2005-08-09 | 2007-03-29 | Revivicor, Inc. | Transgenic ungulates expressing ctla4-ig and uses thereof |
WO2007047539A2 (en) * | 2005-10-14 | 2007-04-26 | Medtronic, Inc. | Localized delivery to the lymphatic system |
WO2007076032A2 (en) * | 2005-12-20 | 2007-07-05 | Bristol-Myers Squibb Company | Compositions and methods for producing a composition |
AR058568A1 (es) * | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
US7510844B2 (en) | 2006-01-24 | 2009-03-31 | Bristol-Myers Squibb Company | CD86 and CD80 receptor competition assays |
US20090029904A1 (en) * | 2006-07-21 | 2009-01-29 | Sean Oldham | Compositions and methods for treatment of insulin-resistance diseases |
WO2008014035A2 (en) * | 2006-07-25 | 2008-01-31 | The Regents Of The University Of California | Modulation of nkg2d and method for treating or preventing solid organ allograft rejection |
AU2007288368B2 (en) * | 2006-08-18 | 2013-07-04 | Coimmune, Inc. | Use of CD83 in combination therapies |
GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
PL2612868T3 (pl) * | 2007-11-01 | 2018-12-31 | Astellas Pharma Inc. | Immunosupresyjne polipeptydy i kwasy nukleinowe |
US20090191608A1 (en) * | 2008-01-22 | 2009-07-30 | Baylor Research Institute | Pancreatic Islet Cell Preparation and Transplantation |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
CA2737461A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
WO2010040105A2 (en) | 2008-10-02 | 2010-04-08 | Trubion Pharmaceuticals, Inc. | Cd86 antagonist multi-target binding proteins |
WO2010049935A1 (en) * | 2008-10-30 | 2010-05-06 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
CA2937492C (en) | 2008-11-11 | 2019-08-13 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
AU2010278894B2 (en) | 2009-07-30 | 2014-01-30 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
JP2013501528A (ja) | 2009-08-14 | 2013-01-17 | レビビコア, インコーポレイテッド | 糖尿病の処置のためのマルチ・トランスジェニック・ブタ |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
EP2545073B1 (en) | 2010-03-12 | 2015-09-30 | AbbVie Biotherapeutics Inc. | Ctla4 proteins and their uses |
US9527912B2 (en) | 2010-05-17 | 2016-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade |
SG188471A1 (en) | 2010-09-08 | 2013-04-30 | Yeda Res & Dev | An immunosuppressive drug combination for a stable and long term engraftment |
ES2589678T3 (es) | 2010-09-08 | 2016-11-15 | Yeda Research And Development Co. Ltd. | Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma |
ES2680636T3 (es) | 2011-02-14 | 2018-09-10 | Revivicor Inc. | Cerdos genéticamente modificados para xenotrasplante de xenoinjertos vascularizados y derivados de los mismos |
CA2848121C (en) | 2011-09-08 | 2022-07-05 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
KR20150033703A (ko) | 2012-06-27 | 2015-04-01 | 오르반 바이오테크 엘엘씨 | 당뇨병 치료를 위한 ctla4 융합 단백질 |
US20140112958A1 (en) | 2012-10-24 | 2014-04-24 | Mwm Biomodels Gmbh | Pancreatic islets of transgenic LEA29Y animals for treating diabetes |
EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
BR112015024516A2 (pt) | 2013-03-28 | 2017-10-24 | Bristol Myers Squibb Co | métodos para identificar pacientes em risco de rejeição resistente ao bloqueio de coestimulação |
WO2014182601A1 (en) * | 2013-05-08 | 2014-11-13 | Children's Medical Center Corporation | A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis) |
PT3091991T (pt) * | 2013-12-13 | 2020-02-04 | Swedish Stromabio Ab | Composições imunomodulatórias |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
CN107969128A (zh) | 2015-04-17 | 2018-04-27 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
WO2017009852A1 (en) | 2015-07-16 | 2017-01-19 | Yeda Research And Development Co. Ltd. | Use of anti third party central memory t cells |
WO2017019214A1 (en) | 2015-07-29 | 2017-02-02 | Musc Foundation For Research Development | Donor organ pre-treatment formulation |
IT201800000534A1 (it) * | 2018-01-03 | 2019-07-03 | Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici. | |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
EP3571295A1 (en) | 2017-01-18 | 2019-11-27 | Yeda Research and Development Co. Ltd | Genetically modified veto cells and use of same in immunotherapy |
US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
CA3077509A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IL92382A (en) * | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
US6905680B2 (en) * | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
WO1993019767A1 (en) | 1992-04-07 | 1993-10-14 | The Regents Of The University Of Michigan | Cd28 pathway immunoregulation |
US5858358A (en) * | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6685941B1 (en) * | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
US6352694B1 (en) * | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5521288A (en) * | 1990-03-26 | 1996-05-28 | Bristol-Myers Squibb Company | CD28IG fusion protein |
US7070776B1 (en) | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
US6090914A (en) * | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
CA2580812A1 (en) | 1991-06-27 | 1993-01-07 | Bristol-Myers Squibb Company | Ctla4 receptor, fusion proteins containing it and uses thereof |
US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5958403A (en) * | 1992-02-28 | 1999-09-28 | Beth Israel Hospital Association | Methods and compounds for prevention of graft rejection |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5773253A (en) * | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
EP0700430B1 (en) | 1993-06-04 | 2005-04-20 | The United States of America as Represented by the Secretary of the Navy | Methods for selectively stimulating proliferation of t cells |
AU7107794A (en) | 1993-06-10 | 1995-01-03 | Regents Of The University Of Michigan, The | Cd28 pathway immunosuppression |
ES2143553T3 (es) | 1993-09-02 | 2000-05-16 | Dartmouth College | Anticuerpos anti-gp39 y sus utilizaciones. |
US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
CA2191586A1 (en) | 1994-06-03 | 1995-12-14 | Carl H. June | Methods for selectively stimulating proliferation of t cells |
US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
WO1995034320A2 (en) | 1994-06-07 | 1995-12-21 | Regents Of The University Of Minnesota | Methods for inhibiting antigen specific t cell responses |
WO1996014865A1 (en) | 1994-11-10 | 1996-05-23 | Repligen Corporation | Methods for inhibiting graft versus host disease in bone marrow transplantation |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
GB9506844D0 (en) * | 1995-04-03 | 1995-05-24 | Armitage Ian M | Pharmaceutical microencapsulation |
US5993800A (en) * | 1995-06-05 | 1999-11-30 | Bristol-Myers Squibb Company | Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US7041634B2 (en) * | 1995-09-27 | 2006-05-09 | Emory University | Method of inhibiting immune system destruction of transplanted viable cells |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
ATE219376T1 (de) * | 1996-03-20 | 2002-07-15 | Bristol Myers Squibb Co | Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung |
KR19980066046A (ko) | 1997-01-18 | 1998-10-15 | 정용훈 | 고역가의 CTLA4-Ig 융합단백질 |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
WO1998056417A1 (en) | 1997-06-11 | 1998-12-17 | The United States Of America, Represented By The Secretary Of The U.S. Department Of The Navy | Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses |
EP1058555B1 (en) | 1998-02-04 | 2004-04-28 | The General Hospital Corporation | Costimulatory blockade and mixed chimerism in allotransplantation |
IL126681A0 (en) | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
AU2001264936A1 (en) | 2000-05-23 | 2001-12-03 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ctla4 gene |
MXPA02011534A (es) | 2000-05-26 | 2004-08-12 | Bristol Myers Squibb Co | Moleculas mutantes ctla4 solubles y uso de las mismas. |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
AU2006203199B2 (en) * | 2000-05-26 | 2009-02-12 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
CA2411962A1 (en) * | 2000-06-09 | 2001-12-20 | Bristol-Myers Squibb Company | Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
CA2413190C (en) | 2000-07-03 | 2009-04-07 | Bristol-Myers Squibb Company | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
WO2002058729A2 (en) * | 2001-01-26 | 2002-08-01 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
US20030031652A1 (en) | 2001-04-16 | 2003-02-13 | Bernhard Hering | Systems and methods for inducing mixed chimerism |
EP1397153B1 (en) * | 2001-05-23 | 2008-04-02 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
PT1576182E (pt) | 2002-12-23 | 2011-01-21 | Bristol Myers Squibb Co | Optimizador da qualidade do produto em processos de cultura celular de mamíferos destinados à produção de proteínas |
PL377731A1 (pl) | 2002-12-23 | 2006-02-06 | Bristol-Myers Squibb Company | Sposoby hodowli komórek ssaczych do wytwarzania białka |
KR20060132541A (ko) | 2003-08-04 | 2006-12-21 | 브리스톨-마이어스 스큅 컴퍼니 | 가용성 ctla4 분자를 사용한 심혈관 질환의 치료 방법 |
-
2002
- 2002-05-23 EP EP02734556A patent/EP1397153B1/en not_active Expired - Lifetime
- 2002-05-23 MX MXPA03010568A patent/MXPA03010568A/es active IP Right Grant
- 2002-05-23 DE DE60225914T patent/DE60225914T2/de not_active Expired - Lifetime
- 2002-05-23 PL PL364578A patent/PL204899B1/pl unknown
- 2002-05-23 PT PT02734556T patent/PT1397153E/pt unknown
- 2002-05-23 JP JP2002590923A patent/JP4837880B2/ja not_active Expired - Fee Related
- 2002-05-23 AT AT02734556T patent/ATE390931T1/de active
- 2002-05-23 AU AU2002305716A patent/AU2002305716B2/en not_active Ceased
- 2002-05-23 ES ES02734556T patent/ES2302811T3/es not_active Expired - Lifetime
- 2002-05-23 CA CA2447921A patent/CA2447921C/en not_active Expired - Fee Related
- 2002-05-23 HU HU0401590A patent/HU229680B1/hu not_active IP Right Cessation
- 2002-05-23 WO PCT/US2002/016708 patent/WO2002094202A2/en active Application Filing
- 2002-05-23 US US10/155,514 patent/US7304033B2/en not_active Expired - Lifetime
- 2002-05-23 CZ CZ2003-3188A patent/CZ305380B6/cs not_active IP Right Cessation
- 2002-05-23 DK DK02734556T patent/DK1397153T3/da active
-
2003
- 2003-11-21 NO NO20035176A patent/NO332465B1/no not_active IP Right Cessation
-
2007
- 2007-10-29 US US11/978,701 patent/US7829534B2/en not_active Expired - Lifetime
-
2008
- 2008-06-09 CY CY20081100608T patent/CY1108127T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA03010568A (es) | 2005-03-07 |
DE60225914T2 (de) | 2009-07-23 |
CA2447921C (en) | 2011-08-09 |
NO20035176L (no) | 2004-01-05 |
CY1108127T1 (el) | 2014-02-12 |
AU2002305716B8 (en) | 2002-12-03 |
JP4837880B2 (ja) | 2011-12-14 |
WO2002094202A3 (en) | 2003-06-26 |
DE60225914D1 (de) | 2008-05-15 |
PL204899B1 (pl) | 2010-02-26 |
US20080160022A1 (en) | 2008-07-03 |
ES2302811T3 (es) | 2008-08-01 |
EP1397153A4 (en) | 2006-01-04 |
CA2447921A1 (en) | 2002-11-28 |
NO20035176D0 (no) | 2003-11-21 |
PT1397153E (pt) | 2008-06-12 |
HUP0401590A3 (en) | 2012-09-28 |
AU2002305716B2 (en) | 2007-10-25 |
CZ305380B6 (cs) | 2015-08-26 |
HU229680B1 (hu) | 2014-04-28 |
EP1397153B1 (en) | 2008-04-02 |
HUP0401590A2 (hu) | 2004-11-29 |
CZ20033188A3 (cs) | 2005-04-13 |
PL364578A1 (en) | 2004-12-13 |
NO332465B1 (no) | 2012-09-24 |
ATE390931T1 (de) | 2008-04-15 |
JP2004535402A (ja) | 2004-11-25 |
US7829534B2 (en) | 2010-11-09 |
US20030022836A1 (en) | 2003-01-30 |
WO2002094202B1 (en) | 2003-07-31 |
US7304033B2 (en) | 2007-12-04 |
EP1397153A2 (en) | 2004-03-17 |
WO2002094202A2 (en) | 2002-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1397153T3 (da) | Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler | |
EA200100992A1 (ru) | Ингибиторы фермента impdh | |
ATE373660T1 (de) | Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes | |
NO20050525L (no) | Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer | |
NO20061194L (no) | Mitotiske kinesininbibitorer | |
ATE447574T1 (de) | 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes | |
EA200601552A1 (ru) | Замещенные конденсированные гетероциклические с-гликозиды | |
DE69417012D1 (de) | Cyclobutan-derivate als inhibitoren der squalen-synthetase und der protein-farnesyltransferase | |
ATE481969T1 (de) | Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes | |
MXPA05012837A (es) | Inhibidores de caspasa y usos de los mismos. | |
EP1794120A4 (en) | peptidase | |
DK1056454T3 (da) | Anvendelse af makrolidforbindelser til behandling af glaukom | |
DK1373220T3 (da) | Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion | |
DK1511472T3 (da) | Anvendelige forbindelser til behandling af Anthrax og hæmning af letalfaktor | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
AR015417A1 (es) | Procedimiento para purificar alatrofloxacino, composiciones, compuestos relacionados y procedimientos para tratar infecciones con dichos compuestos | |
DK0804410T3 (da) | Fremgangsmåde til fremstilling af retrovirale proteaseinhibitor-mellemprodukter | |
DE60329326D1 (de) | Tace inhibitoren | |
FI970279A (fi) | Orgaanisia yhdisteitä | |
NO20010266L (no) | Sykliske forbindelser som kan anvendes ved behandling av dyslipidemi, aterosklerose og diabetes, farmasöytiske preparater og fremstillingsfremgangsmåte | |
EA200500517A1 (ru) | Лечение синдрома х замещёнными тетралинами и инданами | |
ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
BR0313000A (pt) | Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente | |
EA200000522A1 (ru) | 5-htагонисты | |
NO943765L (no) | Aryloksybenzen-herbicidmidler |